Cumberland Pharmaceuticals(US:CPIX) Prnewswire·2024-07-30 20:05Core Viewpoint - Cumberland Pharmaceuticals Inc. is set to release its second quarter 2024 financial results and provide a company update on August 6, 2024, after market close [4]. Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on developing, acquiring, and commercializing unique products that enhance patient care, particularly in the hospital acute care, gastroenterology, and oncology market segments [6]. Product Portfolio - The company has a portfolio of FDA-approved brands, including: - Acetadote® (acetylcysteine) injection for acetaminophen poisoning - Caldolor® (ibuprofen) injection for pain and fever - Kristalose® (lactulose) for constipation - Omeclamox®-Pak (omeprazole, clarithromycin, amoxicillin) for H. pylori infection and related duodenal ulcer disease - Sancuso® (granisetron) transdermal system for nausea and vomiting prevention in chemotherapy patients - Vaprisol® (conivaptan) injection for raising serum sodium levels in hospitalized patients - Vibativ® (telavancin) injection for serious bacterial infections [7]. Clinical Programs - Cumberland is conducting Phase II clinical programs for its ifetroban product candidate, targeting patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. The company has also received FDA clearance to proceed directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis [3].